Generation Bio Co. Stock Price, News & Analysis

Generation Bio (Nasdaq: GBIO) reported significant advancements in its genetic medicine platform for treating hemophilia A, demonstrating up to 205% normal human factor VIII expression in mouse studies using its closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticle (ctLNP) technology. Non-human primate studies showed up to 2% factor VIII expression, with noted variability. The company plans to enhance species translation for further development. Upcoming updates and timing for its first IND submission are expected in 2022.

Generation Bio Co (Nasdaq: GBIO) reported promising preclinical data at the ESGCT Annual Virtual Congress, showcasing the efficacy of their cell-targeted lipid nanoparticle (ctLNP) delivery platform for retinal therapies. The data indicated broad delivery and durable expression of closed-ended DNA (ceDNA) comparable to AAV5, suggesting potential for gene editing in retinal diseases. Financially, they reported a net loss of $31.9 million for Q3 2021, an increase from $20.8 million in Q3 2020, with R&D expenses rising to $22 million. Cash reserves improved to $398.4 million as of September 30, 2021.

Generation Bio Co (Nasdaq: GBIO) presented new preclinical data at the ESGCT 2021 Annual Virtual Congress, demonstrating effective sub-retinal delivery of closed-ended DNA (ceDNA) using its cell-targeted lipid nanoparticle (ctLNP). The study shows broad photoreceptor distribution and durable expression with ctLNP in rodents, comparable to AAV5. Additionally, ctLNP mRNA delivery in non-human primates indicates potential as a leading non-viral method for gene editing in the retina. This platform aims to address inherited retinal diseases and expand opportunities for gene therapy.

Generation Bio Co. (Nasdaq: GBIO), a leader in genetic medicines for rare and prevalent diseases, announced that its CEO, Geoff McDonough, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on October 27 at 5:00 p.m. ET. A live webcast will be available on the company's investor website, with a replay accessible for 30 days after the event. The company focuses on innovative genetic therapies through its proprietary non-viral platform, which aims to provide durable treatments and scalable manufacturing for more patients globally.

On October 15, 2021, Generation Bio (Nasdaq: GBIO) announced an upcoming oral presentation at the European Society of Gene and Cell Therapy Annual Virtual Congress, scheduled for October 19-22. The presentation will showcase preclinical advancements in retinal therapies using a novel lipid nanoparticle for broad cellular delivery. Matthew Stanton, Ph.D., emphasized the potential of their non-viral delivery system to address challenges faced by viral gene therapies. Attendees can access the presentation online on October 22 and a recorded version for 30 days afterward.

Generation Bio (Nasdaq: GBIO) reported its second-quarter 2021 financial results, showcasing a cash position of $425.2 million as of June 30, 2021, a notable increase from $262.3 million at the end of 2020. R&D expenses rose to $22.7 million, up from $13.5 million year-over-year. The net loss expanded to $30.8 million, or $0.55 per share, compared to a net loss of $17.7 million or $1.50 per share last year. The company is transitioning to a new manufacturing process and has signed a lease for a 104,000 square feet cGMP facility in Waltham, expected to be operational in 2023.

Generation Bio Co. (Nasdaq: GBIO) announces participation of CEO Geoff McDonough, M.D., in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 on August 10 at 9:10 a.m. ET. The event will focus on the company's innovations in genetic medicines for rare and prevalent diseases. A live webcast will be available on the company's investor website, with a replay accessible for 30 days post-event. Generation Bio's unique platform, utilizing closed-ended DNA and advanced lipid nanoparticle delivery, aims to provide durable treatments and scalable manufacturing for genetic therapies.

Generation Bio (Nasdaq: GBIO) announced a transition to rapid enzymatic synthesis (RES) for its closed-ended DNA manufacturing across all programs, enhancing quality, scale, and speed. A lease agreement was signed for a cGMP manufacturing facility in Waltham, MA, expected to be operational in 2023. The company anticipates submitting an IND application for hemophilia A by year-end 2023, with factor VIII expression data anticipated in late 2021. Despite incurring $104 million in lease costs and $45 million in facility investments, the company expects its cash runway to remain sufficient until 2024.

Generation Bio, a leader in genetic medicines, announced that CEO Geoff McDonough will present at the William Blair Biotech Focus Conference on July 15, 2021, at 9:00 a.m. ET. The event will feature a live webcast available on their investor website, with a replay accessible for 30 days. Generation Bio focuses on developing non-viral gene therapies aimed at providing durable treatments for various diseases. Their innovative platform utilizes closed-ended DNA and a specialized delivery system to target specific tissues for effective therapy.